Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vir Biotechnology, Inc. (VIR)

27.61   0.58 (2.15%) 12-02 16:00
Open: 26.61 Pre. Close: 27.03
High: 27.66 Low: 26.61
Volume: 626,920 Market Cap: 3,675(M)

Technical analysis

as of: 2022-12-02 4:27:03 PM
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time.
Target: Six months: 33.18     One year: 38.75
Support: Support1: 24.18    Support2: 21.57
Resistance: Resistance1: 28.4    Resistance2: 33.18
Pivot: 27.25
Moving Average: MA(5): 27.41     MA(20): 27.09
MA(100): 24.51     MA(250): 26.89
MACD: MACD(12,26): 1.1     Signal(9): 1.2
Stochastic oscillator: %K(14,3): 64.4     %D(3): 65.8
RSI: RSI(14): 61
52-week: High: 58  Low: 18.04
Average Vol(K): 3-Month: 991 (K)  10-Days: 638 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ VIR ] has closed below upper band by 24.0%. Bollinger Bands are 72.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 27.68 - 27.81 27.81 - 27.93
Low: 26.28 - 26.43 26.43 - 26.57
Close: 27.36 - 27.6 27.6 - 27.82

Company Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Headline News

Sat, 03 Dec 2022
Andaman Islands named after 4 Param Vir Chakra recipients from Himachal, read about their valour - The Newz Radar

Sat, 03 Dec 2022
Bhai Vir Singh's birth anniversary: Time to redefine human connect with nature, say scholars - The Tribune India

Fri, 02 Dec 2022
Rude Food by Vir Sanghvi: The seaside foodie kingdom - Hindustan Times

Fri, 02 Dec 2022
Skip Barber Racing School relocates headquarters to VIR - RACER

Fri, 02 Dec 2022
2 Fast-Growing Healthcare Stocks to Buy and Hold - The Motley Fool

Thu, 01 Dec 2022
Equities Analysts Offer Predictions for Vir Biotechnology, Inc.'s FY2022 Earnings (NASDAQ:VIR) - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 133 (M)
Shares Float 81 (M)
% Held by Insiders 13.5 (%)
% Held by Institutions 76 (%)
Shares Short 4,400 (K)
Shares Short P.Month 4,960 (K)

Stock Financials

EPS 8.5
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 16.15
Profit Margin (%) 48
Operating Margin (%) 67.4
Return on Assets (ttm) 51.3
Return on Equity (ttm) 75.5
Qtrly Rev. Growth 261.5
Gross Profit (p.s.) 4.43
Sales Per Share 17.87
EBITDA (p.s.) 12.09
Qtrly Earnings Growth 58.5
Operating Cash Flow 1,640 (M)
Levered Free Cash Flow 1,180 (M)

Stock Valuations

PE Ratio 3.24
PEG Ratio 0.9
Price to Book value 1.7
Price to Sales 1.54
Price to Cash Flow 2.24

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.